Synopsis
Select licensed weight-management medicines through current NICE and commissioning criteria, prescribe with reproductive and acute-adverse-effect safeguards, and stop or escalate treatment using agreed outcomes.
- Anti-obesity medicine is an adjunct to an individualised nutrition, activity and behavioural programme, not a cosmetic shortcut or a replacement for follow-up.
- Eligibility differs by product, NICE technology appraisal, comorbidity, BMI, ethnicity, service setting and local phased commissioning; verify the live pathway before promising access.
- As at 27 August 2026, licensing was broader than NHS access: NICE TA875 described the commissioned 2.4 mg weekly semaglutide injection route, while the MHRA had also authorised 7.2 mg injected Wegovy, 25 mg oral Wegovy and Foundayo (orforglipron); a licence does not itself create NICE recommendation, NHS funding or local availability.
- Tirzepatide is a weekly dual GIP/GLP-1 agonist; semaglutide and liraglutide are GLP-1 receptor agonists; orlistat reduces intestinal fat absorption.
- Escalate incretin doses gradually to reduce gastrointestinal adverse effects, and never switch products or strengths by presumed dose equivalence.
- Agree a stopping rule before treatment: NICE appraisals commonly use failure to lose a specified percentage after a defined period at treatment dose.
- The MHRA strengthened class warnings in 2026 for acute pancreatitis, including rare necrotising and fatal reports; severe persistent abdominal pain needs urgent assessment.
- GLP-1 and dual GIP/GLP-1 medicines should not be used during pregnancy, when trying to conceive or during breastfeeding, with product-specific washout advice.
- Tirzepatide can reduce oral contraceptive reliability during initiation and dose escalation; use the current MHRA barrier or non-oral contraception advice.
- When diabetes medicines include insulin or sulfonylurea, plan dose review and glucose monitoring to avoid hypoglycaemia as intake and weight change.
- Tell anaesthesia teams about incretin treatment because delayed gastric emptying can increase pulmonary aspiration risk; follow the current procedure-specific policy rather than stopping independently.
- Use only a legitimate prescribed product from a registered pharmacy and ask specifically about private treatment, which may be absent from the NHS medication record.
Key red flags
Severe persistent upper-abdominal pain, often radiating to the back with nausea or vomiting, is not ordinary titration discomfort; stop the incretin medicine and arrange urgent assessment.
Persistent vomiting or diarrhoea, postural symptoms, low urine output and rising creatinine indicate dehydration; temporarily review nephrotoxic or blood-pressure medicines and assess urgently when severe.
A delayed period, planned conception or confirmed pregnancy requires prompt prescriber contact and stopping the incretin under current MHRA advice; do not continue for weight control during gestation.
Sudden painless monocular visual loss or rapid deterioration may represent NAION; the 2026 MHRA communication advises urgent medical or eye-casualty assessment rather than waiting for routine review.
Investigation priorities
Confirm eligibility and provide reproducible outcomes for shared decisions.
Management branches
Behavioural care alone is insufficient and pharmacotherapy is being considered.
- Verify the current NICE appraisal, local commissioning route and product licence, applying ethnicity-adjusted thresholds and weight-related comorbidity criteria correctly.
- Assess pregnancy plans, pancreatitis and gallbladder history, GI motility, diabetes medicines, renal function, eating disorder, anaesthetic plans and ability to follow up.
- Agree product choice, titration, adverse-effect actions, contraception, functional and weight outcomes, stopping rule and likely plan if weight returns after cessation.